Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
| Ominto, Inc.OMNT · Entity 164576 | Director | December 08, 2016 | January 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Ominto, Inc.
Report date December 08, 2016 · Filed January 12, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 90,000 |
Reported balance
After 2016-12-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-08 · Grant · Acquired 70,000 · Balance 90,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting. F3: Options vest over 30 month period. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 120,000 |
Reported balance
After 2016-12-08 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-12-08 · Grant · Acquired 30,000 · Balance 120,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors.
F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting.
F3: Options vest over 30 month period.
F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017.
F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date October 01, 2024 · Filed October 02, 2024
Section 16 reporting ended · disclosed 2024-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,533 |
Ending reported balance
After 2024-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-10-01 · Tax withholding · Disposed 331 · Balance 179,269 F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Row 2 · 2024-10-01 · Tax withholding · Disposed 616 · Balance 178,653 F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Row 3 · 2024-10-01 · Tax withholding · Disposed 662 · Balance 177,991 F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Row 4 · 2024-10-01 · Tax withholding · Disposed 458 · Balance 177,533 F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
Holding disclosure · report date 2024-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021.
F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022.
F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023.
F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 11,182 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001644989-26-000002 · form4-06032026_100625.xml · derivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,182 Underlying: Common Stock · 11,182 shares Expires 2036-06-01 F1 · derivative.exercise_date: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001644989-26-000002 · form4-06032026_100625.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,720 F1 · shares: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:17 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 19,554 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001415889-25-015808 · form4-06052025_090604.xml · derivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,554 Underlying: Common Stock · 19,554 shares Expires 2035-06-03 F1 · derivative.exercise_date: Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 19:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 458 | $40.63 | $18,608.54 |
DisclosureSEC source: 0001127602-24-025005 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,533 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 19:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 662 | $40.63 | $26,897.06 |
DisclosureSEC source: 0001127602-24-025005 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,991 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 19:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 616 | $40.63 | $25,028.08 |
DisclosureSEC source: 0001127602-24-025005 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,653 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 19:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 331 | $40.63 | $13,448.53 |
DisclosureSEC source: 0001127602-24-025005 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,269 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 16:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-023899 · form4.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,477 Underlying: Common Stock · 3,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F5 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 16:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 500 | $46.34 | $23,170.00 |
DisclosureSEC source: 0001127602-24-023899 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.24 to $46.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 16:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 891 | $45.80 | $40,807.80 |
DisclosureSEC source: 0001127602-24-023899 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,100 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.24 to $46.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 16:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,609 | $44.38 | $71,407.42 |
DisclosureSEC source: 0001127602-24-023899 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,991 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.13 to $44.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 16:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 3,000 | $0.46 | $1,371.00 |
DisclosureSEC source: 0001127602-24-023899 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:43 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 36,136 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001415889-24-022937 · form4-09052024_080937.xml · derivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,136 Underlying: Common Stock · 36,136 shares Expires 2034-09-02 F1 · derivative.exercise_date: Vests as to one-third of the shares on each annual anniversary of the date of grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-022199 · form4.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,477 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F5 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 426 | $48.56 | $20,686.56 |
DisclosureSEC source: 0001127602-24-022199 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $48.50 to $48.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Includes 373 shares acquired on July 31, 2024 through the Issuer's Employee Stock Purchase Program. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,574 | $47.94 | $219,277.56 |
DisclosureSEC source: 0001127602-24-022199 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,026 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.46 to $48.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001127602-24-022199 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-020517 · form4.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,477 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,965 | $54.31 | $106,719.15 |
DisclosureSEC source: 0001127602-24-020517 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,227 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.16 to $54.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,035 | $53.72 | $163,040.20 |
DisclosureSEC source: 0001127602-24-020517 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,192 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.16 to $54.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001127602-24-020517 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 458 | $50.19 | $22,987.02 |
DisclosureSEC source: 0001127602-24-020036 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,227 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 662 | $50.19 | $33,225.78 |
DisclosureSEC source: 0001127602-24-020036 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,685 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 616 | $50.19 | $30,917.04 |
DisclosureSEC source: 0001127602-24-020036 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,347 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 331 | $50.19 | $16,612.89 |
DisclosureSEC source: 0001127602-24-020036 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,963 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-018741 · form4.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,477 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F4 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,502 | $48.04 | $120,196.08 |
DisclosureSEC source: 0001127602-24-018741 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.79 to $48.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,498 | $47.15 | $117,780.70 |
DisclosureSEC source: 0001127602-24-018741 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,796 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.75 to $47.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:52 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001127602-24-018741 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| May 13, 2024 Filed May 15, 2024 16:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-015472 · form4.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,477 Underlying: Common Stock · 6,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F5 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| May 13, 2024 Filed May 15, 2024 16:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,200 | $46.55 | $102,410.00 |
DisclosureSEC source: 0001127602-24-015472 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.39 to $46.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2024 Filed May 15, 2024 16:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,500 | $45.73 | $160,055.00 |
DisclosureSEC source: 0001127602-24-015472 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.37 to $46.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2024 Filed May 15, 2024 16:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $44.49 | $13,347.00 |
DisclosureSEC source: 0001127602-24-015472 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,994 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.02 to $44.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2024 Filed May 15, 2024 16:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,000 | $0.46 | $2,742.00 |
DisclosureSEC source: 0001127602-24-015472 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 16:32 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-012998 · form4.xml · derivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,477 Underlying: Common Stock · 6,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 16:32 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,000 | $40.96 | $245,760.00 |
DisclosureSEC source: 0001127602-24-012998 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.54 to $41.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 16:32 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,000 | $0.46 | $2,742.00 |
DisclosureSEC source: 0001127602-24-012998 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012243 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,294 F4 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 662 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012243 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,752 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 616 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012243 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,414 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012243 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,030 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 16:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-24-010133 · form4.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,477 Underlying: Common Stock · 6,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F3 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 16:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1 | $42.58 | $42.58 |
DisclosureSEC source: 0001127602-24-010133 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,361 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 16:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,999 | $41.91 | $251,418.09 |
DisclosureSEC source: 0001127602-24-010133 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,362 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.41 to $42.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 16:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,000 | $0.46 | $2,742.00 |
DisclosureSEC source: 0001127602-24-010133 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:55 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantStock Options (Right to Buy) · Derivative | 16,231 | $58.44 Strike: $58.44 | $948,539.64 |
DisclosureSEC source: 0001127602-24-006230 · form4.xml · derivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,231 Underlying: Common Stock · 16,231 shares Expires 2031-02-15 F3 · derivative.exercise_date: Represents options to purchase shares of Issuer common stock which were granted on February 16, 2024 under the Issuer's 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis, with the first tranche vesting on April 1, 2024. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:55 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 14,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006230 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,361 F1 · shares: Represents annual restricted stock units ("RSUs") awarded to the reporting person, with a vesting commencement date of January 1, 2024 (the "Vesting Commencement Date"). 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. F2 · balance_after: Includes 61 shares acquired on January 31, 2024 under the Employee Stock Purchase Plan. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 12:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 733 | $64.92 | $47,586.36 |
DisclosureSEC source: 0001127602-24-000278 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,488 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 12:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 682 | $64.92 | $44,275.44 |
DisclosureSEC source: 0001127602-24-000278 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,221 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 12:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 327 | $64.92 | $21,228.84 |
DisclosureSEC source: 0001127602-24-000278 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,903 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.